Escherichia coli (E. coli) is a gram-negative bacillus and resident of the normal intestinal
microbiota. However, some E. coli strains can cause diseases in humans, other mammals …

The increasing number of bacterial infections globally that do not respond to any available
antibiotics indicates a need to invest in—and ensure access to—new antibiotics, vaccines …

Shigellosis is a leading cause of diarrheal disease in low-middle-income countries (LMICs).
Effective vaccines will help to reduce the disease burden, exacerbated by increasing …

Shigellosis causes more than 200,000 deaths worldwide and most of this burden falls on
Low-and Middle-Income Countries (LMICs), with a particular incidence in children under 5 …

Shigella spp. that are resistant to almost all antimicrobial classes are increasing in
prevalence and becoming globally dominant. The situation is critical and highlights a trend …

Trained immunity is a long-term memory of innate immune cells, generating an improved
response upon reinfection. Shigella is an important human pathogen and inflammatory …

Objectives Establishing a correlate of protection is essential for the development and
licensure of Shigella vaccines. We examined potential threshold levels of serum IgG to …

Infections with antimicrobial-resistant (AMR) bacteria pose an increasing threat to the ability
to perform surgical procedures, organ transplantation, and treat cancer among many other …

Shigella is a major global pathogen and the etiological agent of shigellosis, a diarrheal
disease that primarily affects low-and middle-income countries. Shigellosis is characterized …

There is now a robust pipeline of licensed and World Health Organization (WHO)–
prequalified typhoid conjugate vaccines with a steady progression of national introductions …